|
Name |
Iridomyrmecin
|
Molecular Formula | C10H16O2 | |
IUPAC Name* |
(4S,4aS,7S,7aR)-4,7-dimethyl-4,4a,5,6,7,7a-hexahydro-1H-cyclopenta[c]pyran-3-one
|
|
SMILES |
C[C@H]1CC[C@H]2[C@@H]1COC(=O)[C@H]2C
|
|
InChI |
InChI=1S/C10H16O2/c1-6-3-4-8-7(2)10(11)12-5-9(6)8/h6-9H,3-5H2,1-2H3/t6-,7-,8+,9+/m0/s1
|
|
InChIKey |
LYEFRAMOOLOUKA-RBXMUDONSA-N
|
|
Synonyms |
Iridomyrmecin; Iridomyrmexin; 485-43-8; (+)-Iridomyrmecin; Iridomirmecina; 9736R92EPU; (4S,4aS,7S,7aR)-4,7-dimethyl-4,4a,5,6,7,7a-hexahydro-1H-cyclopenta[c]pyran-3-one; C09786; AC1L9CSW; UNII-9736R92EPU; NSC-10974; NSC 10974; IRIDOMYRMECIN [MI]; SureCN1649438; IRIDOMYRMECIN, (+)-; CHEBI:5967; SCHEMBL1649438; DTXSID40876125; CYCLOPENTA(C)PYRAN-3(1H)-ONE, HEXAHYDRO-4,7-DIMETHYL-, (4S-(4.ALPHA.,4A.BETA.,7.BETA.,7A.BETA.))-; Q2016116; .ALPHA.-(2-HYDROXYMETHYL-3-METHYLCYCLOPENTANE)PROPIONIC ACID .DELTA.-LACTONE; CYCLOPENTA(C)PYRAN-3(1H)-ONE, HEXAHYDRO-4,7-DIMETHYL-, (4S,4AS,7S,7AR)-; Cyclopenta(c)pyran-3(1H)-one, hexahydro-4,7-dimethyl-, (4S-(4alpha,4abeta,7beta,7abeta))-
|
|
CAS | 485-43-8 | |
PubChem CID | 442427 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 168.23 | ALogp: | 2.6 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 26.3 | Aromatic Rings: | 2 |
Heavy Atoms: | 12 | QED Weighted: | 0.519 |
Caco-2 Permeability: | -4.501 | MDCK Permeability: | 0.00003650 |
Pgp-inhibitor: | 0.005 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.943 |
30% Bioavailability (F30%): | 0.983 |
Blood-Brain-Barrier Penetration (BBB): | 0.648 | Plasma Protein Binding (PPB): | 45.72% |
Volume Distribution (VD): | 1.075 | Fu: | 52.34% |
CYP1A2-inhibitor: | 0.846 | CYP1A2-substrate: | 0.649 |
CYP2C19-inhibitor: | 0.174 | CYP2C19-substrate: | 0.866 |
CYP2C9-inhibitor: | 0.049 | CYP2C9-substrate: | 0.121 |
CYP2D6-inhibitor: | 0.014 | CYP2D6-substrate: | 0.251 |
CYP3A4-inhibitor: | 0.179 | CYP3A4-substrate: | 0.48 |
Clearance (CL): | 13.991 | Half-life (T1/2): | 0.4 |
hERG Blockers: | 0.127 | Human Hepatotoxicity (H-HT): | 0.226 |
Drug-inuced Liver Injury (DILI): | 0.654 | AMES Toxicity: | 0.305 |
Rat Oral Acute Toxicity: | 0.172 | Maximum Recommended Daily Dose: | 0.089 |
Skin Sensitization: | 0.884 | Carcinogencity: | 0.644 |
Eye Corrosion: | 0.889 | Eye Irritation: | 0.929 |
Respiratory Toxicity: | 0.818 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003248 | 0.356 | D0S3WH | 0.309 | ||||
ENC004742 | 0.341 | D0K7LU | 0.262 | ||||
ENC000791 | 0.326 | D0U3GL | 0.237 | ||||
ENC005198 | 0.317 | D0N6FH | 0.219 | ||||
ENC003480 | 0.308 | D04CSZ | 0.216 | ||||
ENC002040 | 0.302 | D04DJN | 0.211 | ||||
ENC001295 | 0.298 | D06HLY | 0.210 | ||||
ENC002880 | 0.298 | D0G6AB | 0.203 | ||||
ENC004835 | 0.295 | D0Y5ZA | 0.203 | ||||
ENC002277 | 0.295 | D04VIS | 0.202 |